Sitemap

Human Health

Animal Health

Investor relations

» Annual General Meeting 2006

» Annual General Meeting 2007

» Annual General Meeting 2008

» Annual General Meetings

» Articles of Association

» Chairman of the Board

» Corporate Governance

» Nomination committee

» Option program

» Remuneration committee

» Tasks for the Board of Directors

» The Board of Directors

» Work plan for the Board of Directors

Management

» Annette Ljungmark

» Julian Aleksov

» Weine Nejdemo

Department Directors

» Amir Tatarevic

» Annette Ljungmark

» Britt-Marie Eriksson

» Hannu Wennonen

» Henrik von Euler

» Lasse Koskenniska

» Margareta Eriksson

» Maria Lundén

» Maria Nylander

Board of Directors

» Bo Cederstrand

» Julian Aleksov

» Peter Ström

Pages

» Animal Health

» Forskning och utveckling

» Funktionsansvariga

» För djurägare

» För läkare

» För patienter

» För veterinärer

» Human Health

» Investor Relations

» Jobba på Oasmia

» Kontakta oss

» Mediakontakt

» Organisation

» Press releases subscription

Press releases

» Approval for Paccal Vet with EMA begins

» Björn Björnsson nominated as new Board Member

» Call to Extraordinary Genral Meeting

» Communique Annual General Meeting 2009

» Communiqué from Extraordinary General Meeting

» FDA grants Expedited Review Status to Paccal Vet

» FDA grants Paclical® Orphan Drug Designation

» Final advice for Oasmia

» Great interest for Oasmia in Budapest

» Interim report May 1 - July 31 2009

» Interim report May 1, 2009 - January 31, 2010

» Interim Report May 2008 - Jan 2009

» Last patient out for Paccal® Vet Phase III study

» Mycket goda kliniska resultat för Paclical

» New license agreement

» Notice of Annual General Meeting

» Notice of Annual General Meeting 2009

» Nytt cancerläkemedel till hund

» Nytt läkemedel för hund mot registrering

» Oasmia accounces license agreement with Abbott

» Oasmia admitted to trading on NASDAQ OMX Stockholm

» Oasmia aims for global registration of Paccal Vet

» Oasmia announces agreement with Zenoaq

» Oasmia announces distribution agreement

» Oasmia announces licensing agreement

» Oasmia appoints market maker

» Oasmia appoints Remium as liquidity provider

» Oasmia bekräftar Orphan Drug-designering

» Oasmia carries out private placement

» Oasmia changes marketplace

» Oasmia changes report publication date

» Oasmia expands license agreement for Paclical Vet

» Oasmia får Orphan Drug-designering

» Oasmia in Barcelona

» Oasmia presented in Copenhagen

» Oasmia presented in Florida

» Oasmia presenterar i Budapest

» Oasmia presents in USA

» Oasmia presents Phase III

» Oasmia proposes new share issue

» Oasmia publishes Interim Report

» Oasmia publishes Listing Prospectus

» Oasmia publishes prospectus

» Oasmia SA.’s commitment in rights issue

» Oasmia starts clinical studies with Doxophos Vet

» Oasmia successfully concludes enrolment

» Oasmia Sweden enters into SEK 75 million SEDA

» Oasmia to NGM Equity

» Oasmia: FDA grants Paccal Vet Minor Use status

» Oasmia’s rights issue fully subscribed

» Paccal VetÂ´s Phase III study submitted to FDA

» Phase III study generates great interest in Europe

» Preliminary results show Phase III met endpoint

» Promising clinical results for Paclical

» Solid scientific evidence for Paccal Vet

» Status börsnotering av Oasmia

» Study shows good tolerance for Doxophos Vet

» The Oasmia share is now traded on Nasdaq OMX

» Two thirds of the patients enrolled

» Year-end report May 1 2009 - April 30 2010

Information from Oasmia

» Presentation at Financial Hearings in Stockholm

» Price to Oasmia

bottom